

# Francesco Spagnolo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8754285/publications.pdf>

Version: 2024-02-01

73  
papers

2,750  
citations

172443

29  
h-index

206102

48  
g-index

81  
all docs

81  
docs citations

81  
times ranked

5048  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. <i>Cancers</i> , 2022, 14, 377.	3.7	17
2	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.9	41
3	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
4	Ipilimumab in Melanoma: An Evergreen Drug. , 2021, , 217-235.		0
5	How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma. <i>Cancers</i> , 2021, 13, 2043.	3.7	18
6	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	2.6	16
7	Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13604.	3.4	18
8	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. <i>Cancers</i> , 2021, 13, 2440.	3.7	6
9	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
10	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. <i>Frontiers in Oncology</i> , 2021, 11, 739006.	2.8	12
11	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	2.8	52
12	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 159, 154-166.	2.8	19
13	Systemic Treatment in Advanced Melanoma. <i>Updates in Surgery Series</i> , 2021, , 167-174.	0.1	0
14	New Melanoma Staging: Prognostic Factors. <i>Updates in Surgery Series</i> , 2021, , 47-53.	0.1	0
15	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , 2021, 11, 672797.	2.8	2
16	HO $\alpha$ 1 downregulation favors BRAF V600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. <i>International Journal of Cancer</i> , 2020, 146, 1950-1962.	5.1	19
17	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097700.	3.2	6
18	Current State of Target Treatment in BRAF Mutated Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 154.	3.5	82

#	ARTICLE	IF	CITATIONS
19	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	3.5	25
20	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
21	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020, 16, 1091-1100.	2.4	3
22	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	3.4	28
23	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 113.	3.5	52
24	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 653-662.	4.2	16
25	Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients. <i>Journal of Translational Medicine</i> , 2020, 18, 78.	4.4	17
26	Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren. <i>Medicine (United States)</i> , 2020, 99, e18078.	1.0	2
27	Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. <i>Clinical Immunology</i> , 2020, 215, 108428.	3.2	15
28	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. <i>Cancers</i> , 2020, 12, 1007.	3.7	19
29	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	2.4	2
30	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
31	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	9.6	78
32	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
33	CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1263-1271.	1.2	16
34	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 69, 21-28.	7.7	31
35	Effect of Age on Melanoma Risk, Prognosis and Treatment Response. <i>Acta Dermato-Venereologica</i> , 2018, 98, 624-629.	1.3	52
36	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	1.8	11
38	Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations. <i>Oncotarget</i> , 2018, 9, 5691-5702.	1.8	9
39	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	1.8	73
40	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	5.9	35
41	Binimetinib for the treatment of NRAS-mutant melanoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 985-990.	2.4	21
42	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	7.7	88
43	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
44	Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. <i>Oncotarget</i> , 2017, 8, 8069-8082.	1.8	34
45	Sun exposure and melanoma prognostic factors. <i>Oncology Letters</i> , 2016, 11, 2706-2714.	1.8	29
46	CARMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. <i>Annals of Oncology</i> , 2016, 27, vi386.	1.2	0
47	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016, 27, 732-738.	1.2	321
48	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.	1.2	32
49	Update on Metastatic Uveal Melanoma: Progress and Challenges. <i>BioDrugs</i> , 2016, 30, 161-172.	4.6	14
50	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 45, 38-45.	7.7	71
51	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	1.6	30
52	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. <i>Oncotarget</i> , 2016, 7, 60858-60871.	1.8	14
53	CARMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21009-e21009.	1.6	0
54	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	2.0	134

#	ARTICLE	IF	CITATIONS
55	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 519-526.	7.7	63
56	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , 2014, 110, 1721-1726.	6.4	53
57	Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. <i>Journal of Surgical Oncology</i> , 2014, 109, 270-274.	1.7	51
58	The treatment of melanoma brain metastases before the advent of targeted therapies. <i>Melanoma Research</i> , 2014, 24, 61-67.	1.2	22
59	<scp>ADAM</scp> 10 correlates with uveal melanoma metastasis and promotes in vitro invasion. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1138-1148.	3.3	25
60	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
61	Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. <i>Archives of Dermatological Research</i> , 2014, 306, 521-526.	1.9	31
62	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. <i>Oncotarget</i> , 2014, 5, 10206-10221.	1.8	104
63	BeyPro1: A phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with vemurafenib, with the association of vemurafenib plus fotemustine.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9109-TPS9109.	1.6	0
64	Regenerative Surgery for the Definitive Repair of Chronic Ulcers. <i>Plastic and Reconstructive Surgery</i> , 2013, 131, 666e-668e.	1.4	0
65	Treatment of metastatic uveal melanoma with intravenous fotemustine. <i>Melanoma Research</i> , 2013, 23, 196-198.	1.2	30
66	Regenerative Surgery for the Definitive Repair of a Vasculitic Nonhealing Ulcer Using Platelet-derived Growth Factors and Noncultured Autologous Cell Suspension. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2013, 1, 1-3.	0.6	20
67	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	8.6	23
68	Regenerative Surgery for the Definitive Surgical Repair of Enterocutaneous Fistula. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 391e-392e.	1.4	5
69	Uveal melanoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 549-553.	7.7	120
70	Upcoming strategies for the treatment of metastatic melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 177-184.	1.9	44
71	Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. <i>In Vivo</i> , 2012, 26, 147-50.	1.3	5
72	CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment with adalimumab: Challenge and dechallenge study. <i>Clinical Immunology</i> , 2010, 135, 499-500.	3.2	7

#	ARTICLE	IF	CITATIONS
73	Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab. International Immunopharmacology, 2010, 10, 827-828.	3.8	34